Crestview Clinical Laboratory is categorized under Medical Labs in Fresno, CA and active since 2010.
Crestview Clinical Laboratory was established in 2010, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Medical Labs business, which does work in the B2C market, and is classified as a Medical Labs, under code number 6214930 by the NAICS.
If you are seeking more information, feel free to contact Jonathan D Quinones at the company’s single location by writing to 3233 North Chestnut Avenue # 109, Fresno, California CA 93726 or by phoning (559) 452-9001. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Crestview Clinical Laboratory |
| Contact Person: | Jonathan D Quinones |
| Address: | 3233 North Chestnut Avenue # 109, Fresno, California 93726 |
| Phone Number: | (559) 452-9001 |
| Annual Revenue (USD): | $1.000.000 to $2.499.999 |
| Founded: | 2010 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Medical Labs |
| SIC Code: | 8071 |
| NAICS Code: | 6214930 |
| Share This Business: |
Crestview Clinical Laboratory was started in 2010 to provide professional Medical Labs under the SIC code 8071 and NAICS code 6214930. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Jonathan D Quinones for inquiries that concern Crestview Clinical Laboratory by calling the company number (559) 452-9001, as your correspondence is most welcome. Additionally, the physical location of the single location of Crestview Clinical Laboratory can be found at the coordinates 36.78016,-119.73642 as well as the street address 3233 North Chestnut Avenue # 109 in Fresno, California 93726.
For its online presence, you may visit Crestview Clinical Laboratory’s website at and engage with its social media outlets through on Twitter and on Facebook.